Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Kleresca® releases unique biophotonic rosacea treatment

Ballerup, Denmark, August 2018. Kleresca®, a medical technology company focused on the development and commercialisation of a unique biophotonic technology in dermatology, today announced the release of a new treatment for rosacea.A new biophotonic treatment for rosacea is now available to patients through aesthetic clinics across 10 markets including Denmark, UK, France, Spain, Italy, Germany, Belgium, Norway, Australia and Switzerland.   The treatment is based on Kleresca®’s unique and patented biophotonic technology which uses fluorescent light energy to stimulate the skin’s own

NetEnt launches Berryburst times two as it debuts MAX product line

NetEnt has launched Berryburst and Berryburst MAX – the first double release from its groundbreaking, mixed volatility product line.Berryburst is a frenzy of floating and fluctuating fruity fragments in a 5-reel, 3-row video slot. It features the repeatedly successful Cluster Pays™ mechanic allowing players to see big wins together with the proven top performing expanding, stacked wild re-spins mechanic, but now across all 5 reels. Berryburst MAX broadens the new game’s appeal by offering a much higher win potential using the same NetEnt game mechanics as the regular version.

Invitation to presentation of Immunovia´s interim report January-June 2018 and comments to the previously published autoimmunity study results

Lund (Sweden) - Immunovia will publish the company’s interim report for the period January-June 2018 on Friday, August 24, at 08:30 a.m. CET.Immunovia invites to a teleconference (in English) for investors, analysts and media on August 24, at 4:00 – 5:00 p.m. CET. Mats Grahn, CEO will present Immunovia and comment on the interim report, as well as comment on the press release of August 22 regarding autoimmunity study results, followed by a Q&A-session. Please call in a few minutes in advance. To attend, please dial-in at one of the numbers below from: Telephone details:SE:

Magnolia Bostad appoints Thomas Persson

Thomas Persson has been recruited to Magnolia Bostad as Regional Manager Öst and Senior Account Manager.Since it started, Magnolia Bostad has expanded strongly and today has over 6,700 units sold in production. The company is an urban developer with a further 17,700 residencies in its project portfolio consisting of rental apartments, tenant-owned apartments, residential care housing and hotels.  ”Thomas is one of the industry's most talented people and will be a major asset in our continued development,” says Fredrik Lidjan, CEO of Magnolia Bostad. Thomas Persson was previously at

Interim Report January - June 2018 Rabbalshede Kraft AB (publ)

Service Operations signed a new service agreement with Kalix Wind AB during the first half of the year. Rab­balshede Kraft manages a total of 186 turbines, of which 101 are own or co-owned · In May, Business Development acquired three operational wind turbines located in Falkenberg, Hjo and Skara · Production for the company’s own farms totaled 301,850 MWh, of which 212,802 were own and 89,048 co-owned; production was negatively impacted by poor wind condi­tions during the first quarter but rebounded, primarily in June. During the period, the company had a high level of availability, nearly

Hufvudstaden welcomes HUGO BOSS to Gothenburg

HUGO BOSS is due to open its first BOSS store in the Fredstan area of Gothenburg at the end of 2018. Located in the Hufvudstaden property at Fredsgatan 2, the store will have approximately 350 square metres of floor space on two levels, with both womenswear and menswear. The establishment of the international brand BOSS is entirely in line with the Hufvudstaden strategy of developing and reinforcing the Fredstan area.“Hufvudstaden’s aim is to offer successful retail and office tenants prime business locations in central Stockholm and central Gothenburg. We are therefore extremely pleased

STRAX: INTERIM REPORT NO 2 FOR THE FINANCIAL YEAR 2018

STRAX is taking immediate action to adjust to a rapidly changing business environment, with significant cost reductions and investments ine-commerce as well as digitalization tools to future proof the business, whilst continuing to pursue the house of brands strategy.· The Group’s sales for the period January 1 – June 30, 2018, amounted to MEUR 45.8 (43.5), gross margin increased to 32.5 (27.9) percent. · The Group’s result for the period January 1 – June 30, 2018, amounted to MEUR 0.2 (2.2) corresponding to EUR 0.02 (0.02) per share. Equity as at June 30, 2018 amounted to MEUR 20.9 (

VTT’s robot car, Martti, now “speaks 5G” and takes another step towards full automation

New 5G solutions catapult Finland to the 5G eraVTT Technical Research Centre of Finland and Nokia have joined forces to hook the VTT’s robot car, Martti, up to a 5G network, which allows the car to detect objects with improved range and share its observations with other vehicles. This also takes Martti a step closer to highly automated driving. The safety of road users also improves as new solutions and services based on 5G technology become more widely available.VTT is currently coordinating a project called 5G-Safe, which is aimed at piloting new solutions and finalising them on the

Lipidor gets go-ahead for Phase III Clinical Study of new Calcipotriol Spray treatment for psoriasis

India’s CDSCO (Central Drugs Standard Control Organization) has approved Phase III Trials of a new topical anti-psoriatic spray developed by Swedish company Lipidor. The new spray is expected to overcome patient non-compliance, a major problem for traditional psoriasis creams and ointments.   It is exceptionally fast-drying and easy to apply.Calcipotriol Spray consists of the generic Vitamin D analogue, Calcipotriol, formulated in Lipidor´s patented lipid-based drug delivery technology, AKVANO®. Lipidor has developed the clinical trial material (CTM) in cooperation with Swiss API supplier

SUMMARY OF INTERIM REPORT JANUARY - JUNE 2018

Targets in the mine construction are according to schedule and budget The processing plant in August 2018 SECOND QUARTER 2018  · Net profit was -7.9 MSEK (-2.4) and earnings per share were -0.06 SEK (-0.04). · The Group sales was 31 KSEK (60). · Investments were 50.4 MSEK (6.5). · Arto Suokas was appointed CEO of the subsidiary Sotkamo Silver Oy, Arttu Ohtonen was appointed executive vice president of Sotkamo Silver AB. · Topping-out ceremony was on June 28th and the constructions of the Silver Mine project commenced according to the planned production

NextCell's largest shareholder Diamyd Medical exercise all of its warrants

Stem cell company NextCell Pharma AB ("NXTCL") announces today, that its largest shareholder, Diamyd Medical AB, will exercise all its 296 800 series TO1 warrants. Diamyd will exercise the warrants during the subscription period which runs during the period 23rd August – 13th September 2018. This represents an investment total of SEK 1 484 000, corresponding to approximately 10 % of the outstanding warrants.The diabetes Company Diamyd Medical is one of the main owners of NextCell Pharma, with a shareholding of approximately 14 %. In addition to its current shares, Diamyd Medical also has

Polygiene AB (publ.) Interim Report 1 Januari–30 June 2018

Strong growth in April and May and earnings improveQ2 in brief · In the second quarter, net sales were to MSEK 16.6 (14.6), which corresponds to a 14% increase compared to the same period last year. · The operating profit/loss (EBIT) for the period improved compared to the same period last year and amounted to MSEK -1.9 (-3.7). · Cash flow for the second quarter was MSEK -4.2 (-3.5). · The gross margin amounted to 63% (65%). ·  Strong growth during the first two months of the quarter temporarily slackened off in June. The third quarter initially shows signs of strong growth.

ChromoGenics receives order of approximately 220 sqm ConverLight® dynamic glass to Åke Sundvall

ChromoGenics AB (publ) has signed an agreement with Åke Sundvall Byggnads AB to deliver ConverLight® to the project Knäckepilen in Uppsala.ChromoGenics has signed an agreement to deliver approximately 220 sqm of dynamic glass to the project Knäckepilen at Gränbystaden in Uppsala, where Åke Sundvall builds condominiums. ConverLight® will be delivered during the second half of 2018, and time for moving in to the apartments is scheduled for the first quarter of 2019. "People need daylight. In the project Knäckepilen we have focused on innovative architecture and integrated large glass

Interim report second quarter 2018

During the second quarter 2018 sales for PowerCell Sweden AB (publ) more than doubled from MSEK 6.0 to MSEK 13.5 compared to the same period last year, driven by increased customer activities and orders. Operating income for the period was MSEK -19.3 (-18.0).“The awareness about the acute climate situation is increasing and driving interest in us and our products”, Per Wassén, CEO of PowerCell said. “At the same time we continue our structured work to step by step build the company to be better able to both support and to benefit from the necessary transformation.”The English version is

Interim report April - June 2018

Second quarter · Net sales amounted to MSEK 6.1 (28.5)  · EBITDA amounted to MSEK -1.7 (2.3)  · EBIT amounted to MSEK -3.9 (-2.8)  · EBT amounted to MSEK -4.0 (-5.5)  · Earnings per share before dilutions amounted to SEK -0.08 (-0.15)  · Listed on Oslo Stock Exchange, Merkur Market  First half year · Net sales amounted to MSEK 13.6 (57.6)  · EBITDA amounted to MSEK -5.9 (4.3)  · EBIT amounted to MSEK -10.3 (-5.7)  · EBT amounted to MSEK -14.4 (-11.3)  · Earnings per share before dilutions amounted to SEK -0.31 (-0.33)  Significant events after the

Resurs Bank issues SEK 700 million of senior unsecured bonds

Resurs Bank AB, a wholly owned subsidiary of Resurs Holding AB (Nasdaq Stockholm: RESURS), has issued SEK 700 million of senior unsecured bonds in the Nordic market. The 3 year bonds (with maturity August 2021) will be listed on Nasdaq Stockholm. The offer attracted very strong demand and resulted in an oversubscribed orderbook.The bonds are issued under Resurs Bank’s MTN programme with a total frame of SEK 8 billion and pays a coupon of 3m Stibor + 1.50%. Settlement date will be 30 August 2018 and maturity date 30 August 2021.Nordea and Swedbank acted as joint book runners in the

Resurs Bank issues SEK 700 million of senior unsecured bonds

Resurs Bank AB has issued SEK 700 million of senior unsecured bonds in the Nordic market. The 3 year bonds (with maturity August 2021) will be listed on Nasdaq Stockholm. The offer attracted very strong demand and resulted in an oversubscribed orderbook.The bonds are issued under Resurs Bank’s MTN programme with a total frame of SEK 8 billion and pays a coupon of 3m Stibor + 1.50%. Settlement date will be 30 August 2018 and maturity date 30 August 2021.Nordea and Swedbank acted as joint book runners in the transaction. For additional information:Peter Rosén, CFO & Head of IR, peter.

Interim Report Q2 2018: Strong EPS growth and rapid revenue growth in the US

Second quarter 2018 · Revenue increased to SEK 48.1 (42.7) million. Revenue from affiliate operations rose to SEK 47.4 (40.3) million. · EBITDA increased to SEK 30.5 (25.9) million and was negatively impacted by SEK 0.7 million in expenses attributable to switching its listing to Nasdaq First North Premier. · Profit after tax rose to SEK 22.0 (8.0) million. · Earnings per share increased to SEK 0.31 (0.13). · Total NDC growth increased 21%; largest vertical Casino increased the number of NDCs by 36%. First half 2018 · Revenue increased to SEK 92.0 (83.6) million.

The subscription period of the series TO 1 warrants starts today

Stem cell company NextCell Pharma AB ("NXTCL") announces that today, 23rd of August 2018, marks the start of the subscription period of the series of TO 1 series warrants which were issued as part of the company's issue of units during the spring of 2017. The subscription period will end on the 13th of September 2018. Holders of the series TO 1 warrants are entitled to subscribe for a new share for each warrant at a price of SEK 5.00 per share. If all of the series TO 1 warrants are exercised, 2 860 940 new shares will be issued and NXTCL is receives approximately MSEK 14.3 before issue costs.

Diamyd Medical exercises all of its warrants in NextCell Pharma

Diamyd Medical invests another SEK 1.5 million in the stem cell company NextCell Pharma AB by exercising all of the Company’s warrants of the TO1 Series in NextCell Pharma. Diamyd Medical holds 296,800 warrants, corresponding to approximately 10.4 % of the total number of outstanding warrants.Diamyd Medical is one of the main shareholders of NextCell Pharma, with a shareholding of approximately 13.8%. At full utilization rate of all outstanding warrants of series TO 1, a total of 2 860 940, Diamyd Medical will after the warrants have been converted to shares, hold approximately 12.9% of

Fortum Foundation awards more than 680,000 euros in scholarships for global energy sector research

FORTUM CORPORATION ONLINE NEWS 23 August 2018  In 2018, Fortum Foundation awarded a total of more than 680,000 euros to 38 research projects. This year’s Fortum Foundation scholarship distribution event was held on 20 August 2018 at Neste Oyj’s Head Office in Keilaranta, Espoo. “Both founders of the Foundation, Fortum and Neste, are experiencing significant change in the business environment. The megatrends driving the change, like digitalisation, urbanisation, and changing consumer behaviour, are visible in the everyday life of people, e.g. in the electrification of transportation,

SimCorp reports revenue growth of 17% and EBIT margin of 22% in H1 2018

Company Announcement no. 11/2018  H1 2018 highlights: · Reported revenue was EUR 172.8m, an increase of 16.7% when compared with H1 2017, and an increase of 21.1% when measured in local currencies. As SimCorp Italiana, acquired in August 2017, accounted for 7.7%-points of the increase, organic revenue growth was 13.4%. · EBIT was EUR 37.4m compared with EUR 23.4m in H1 2017. EBIT stemming from SimCorp Italiana accounted for EUR 5.4m. Currency fluctuations impacted EBIT negatively by EUR 3.2m during the first half year.   · EBIT margin was 21.6% compared with 15.8% in H1

There are no items matching the current filter
There are no more items matching the current filter
Back to top